T2 Biosystems, Inc. (NASDAQ: TTOO), shares jumped 51.67% to $3.64 in the pre-market session. Since the beginning of the year, the share price has increased by 160.87%. The last 5 trades were up 18.81%, and the last 30 days up 70.21%. With a market cap of 355.09M, the Company saw its share price increased 42.01% in the past 6 months.
So, the news is…
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
T2 Biosystems, Inc. (NASDAQ: TTOO), has announced that its T2SARS-CoV-2 Panel—a clinical detection test that identifies SARS-CoV-2, the virus infamous for COVID-19 infections—is capable of tracking Brazil (P.1) strain of the SARS-CoV-2 virus, which has lately been reported to be present in the United States.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
‘We continue to actively monitor new viruses to confirm that our technology remains a trustworthy deterrent tool for the many health care workers and patients that need our services during this time,’ says T2 Biosystems’ President and CEO, John Sperzel.
The Brazil variant is similar to the variants found in the United Kingdom (B.1.1.7) and South Africa (B.1.351), but more mutations are located in the S gene, which encodes the spike protein. Based on the Brazil variant’s specific sequence analysis, it was confirmed that the T2SARS-CoV-2 Panel could detect this variant reliably and with high confidence. These analyses go beyond the Panel’s previously announced capability to see the B.1.1.7 and B.1.351 variants.
To ensure that the T2SARS-CoV-2 Panel will identify the latest Brazil (P.1) version, a silicon analysis was conducted using the genome sequences contained in the GISAID database. SARS-CoV-2 (P.1) sequences were tested for compatibility with the primer and probe sequences of the T2SARS-CoV-2 row. This Research has shown that the T2SARS-CoV-2 Panel can identify the Brazilian variant SARS-CoV-2.
The T2SARS-CoV-2 line, which indicated a therapeutic sensitivity of 95% and a precision of 100%, results in less than two hours of usage of the upper respiratory swab sample. The Research is carried out by the Company’s FDA-cleared and completely automatic T2Dx Instrument, capable of conducting seven experiments concurrently and up-to 60 samples a day.
Experts maintain we are in the prime of the Healthcare industry. Diagnostics &Researchis giving us insight into preventing and treating previously unknown diseases. The Healthcare industry is sure to offer considerable returns to investors during this period if it can justify its products to the authorities.